AURORA, ON--(Marketwired - Apr 29, 2015) - Helix BioPharma Corp. (
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRES OR DISSEMINATION IN THE UNITED STATES
Helix BioPharma Corp. (
The terms of this second private placement financing, which are the same as those offered in the first, are for the purchase of common shares at $1.10 per share and include one warrant per share at an exercise price of $1.54 and have an expiry of five years from the date of issue.
ACM Alpha Management Consulting Est. provided financial advisory services to Helix in connection with both private placements.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".
This press release is not an offer of securities for sale in the United States. Helix's common shares have not been registered under the Securities Act of 1933 , as amended, and may not be offered or sold in the United States absent an exemption from registration thereunder.
Forward-Looking Information and Risks and Uncertainties
This news release contains certain forward-looking statements and information (collectively, "forward-looking information") within the meaning of applicable Canadian securities laws. Forward-looking information means disclosure regarding possible events, conditions or other matters that is based on assumptions about future economic conditions and courses of action and includes statements regarding plans, goals, objectives, intentions and expectations with respect to Helix's future business, operations, research and development and other information in future periods. Forward-looking information includes, without limitation, statements relating to the expected net proceeds from the offering and other statements which may be identified by words including, without limitation, "expect" and other similar expressions, which are intended to provide information about management's current plans and expectations regarding the business and operations of Helix.
Although Helix believes that the expectations reflected in such forward-looking information are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation that Helix's costs in connection with the private placement are higher than anticipated and those risks and uncertainties affecting Helix as more fully described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking information, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking information.
Forward-looking information is based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.
Investor Relations: Helix BioPharma Corp. Tel: 905 841-2300 Email: ir@helixbiopharma.com
